NSABP B-55/BIG 6-13 A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Reminder! ENROLLMENT NOTICE: SYSTEM MAINTENANCE
Users will not be able to enroll to protocol NSABP-B-55 on Monday, January 23, 2017,
between 1:00 PM and 3:00 PM U.S. Eastern Time, due to system maintenance.
For assistance, call Randomization Support at 716-834-0900 ext. 7301.